Scott Tavernini

Mr. Scott Tavernini


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Journal of Aerosol Science
Verified
Journal Article
Closed access
STScott Tavernini
Scott Tavernini
TCTanya K. Church
Tanya K. Church
DLDavid A. Lewis
David A. Lewis
AMAndrew Martin
Andrew Martin
WFWarren H. Finlay
Warren H. Finlay

Verified
Journal Article
Open access
PDF file
PVPaola Vottero
Paola Vottero
STScott Tavernini
Scott Tavernini
ASAlessandro Santin
Alessandro Santin
DSdavid e. scheim
david e. scheim
Jack TuszynskiJack Tuszynski
Jack Tuszynski
MAMaral Aminpour
Maral Aminpour
Hypercoagulability and formation of extensive and difficult-to-lyse microclots are a hallmark of both acute COVID-19 and long COVID. Fibrinogen, when converted to fibrin, is responsible for clot formation, but abnormal structural and mechanical clot properties can lead to pathologic thrombosis. Recent experimental evidence suggests that the spike protein (SP) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may directly bind to the blood coagulation factor fibrinogen and induce structurally abnormal blood clots with heightened proinflammatory activity. Accordingly, in this study, we used molecular docking and molecular dynamics simulations to explore the potential activity of the antiparasitic drug ivermectin (IVM) to prevent the binding of the SARS-CoV-2 SP to fibrinogen and reduce the occurrence of microclots. Our computational results indicate that IVM may bind with high affinity to multiple sites on the fibrinogen peptide, with binding more likely in the central, E region, and in the coiled-coil region, as opposed to the globular D region. Taken together, our in silico results suggest that IVM may interfere with SP–fibrinogen binding and, potentially, decrease the formation of fibrin clots resistant to degradation. Additional in vitro studies are warranted to validate whether IVM binding to fibrinogen is sufficiently stable to prevent interaction with the SP, and potentially reduce its thrombo-inflammatory effect in vivo.